You just read:

Spherix Global Insights' Quarterly Update on the Multiple Sclerosis Market Reveals a Unique Role for Genzyme's Aubagio As the Only Oral Standard-Efficacy Therapy for First-Line Treatment of Relapsing-Remitting Multiple Sclerosis

News provided by

Spherix Global Insights

Dec 11, 2018, 08:00 ET